TTrialPathMatch Me to Trials
← Back to study

Eligibility check

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Step 1 of 5

Where are you located?

We confirm your state so we only show studies you can actually reach.

Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.